Skip to main content
Premium Trial:

Request an Annual Quote

Hyrax Biosciences, Roche Diagnostics Form SARS-CoV-2 Sequencing Tech Alliance

NEW YORK — South African bioinformatics firm Hyrax Biosciences said on Tuesday that it has signed an agreement to comarket its Exatype automated DNA analysis platform with Roche Diagnostics' research-use-only KAPA HyperCap SARS-CoV-2 panel.

Financial and other terms of the deal were not disclosed.

According to Hyrax, Roche's KAPA HyperCap workflow allows one-day sample preparation while the SARS-CoV-2 panel provides high specificity, uniformity, and success rates from low viral load inputs. The Exatype platform automates sequence analysis and includes SARS-CoV-2 lineage/clade typing algorithms for read mapping and variant calling.

"Pairing our Exatype analysis platform with Roche's KAPA HyperCap SARS-CoV-2 panel ensures high and uniform coverage of the viral genome, which is of the utmost importance in confident identification of emerging isolates and variants," Hyrax CEO Simon Travers said in a statement. "Combining these technologies into a single workflow will lead to higher quality results and increased reliability of sequencing-based viral genotyping."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.